Moderna Shares Drop 7% as Pfizer Projects $10B-$15B mRNA Vaccine Market by 2030

Trending News 🌥️

Moderna ($NASDAQ:MRNA) is a biotechnology company, focused on developing mRNA (messenger ribonucleic acid) therapies and vaccines, with the aim of creating breakthrough medical treatments. Moderna’s stock dropped by 7% on Monday following bullish projections from competitor Pfizer regarding its mRNA-based vaccine franchise. The company estimates that its mRNA vaccines could create a commercial market of between $10B-$15B by 2030, including its Comirnaty COVID-19 vaccine, as well as other mRNA shots for flu and shingles. The drop in Moderna’s stocks came as a surprise, as the company has seen a surge in its share price this year due to the success of its mRNA-based COVID-19 vaccine. Moderna has been aggressively investing in research and development to capitalize on the opportunity presented by mRNA-based vaccines. The company is working on other mRNA treatments for diseases such as cancer and infectious diseases, as well as developing new technologies to allow faster and more efficient production of vaccines.

However, Pfizer’s announcement that it expects a market of $10B-$15B for its mRNA vaccines by 2030 has put pressure on Moderna’s stock. The company will now have to compete with Pfizer for a share of that market, and it remains to be seen how well it will be able to do so. Overall, it is clear that the competition in the mRNA-based vaccine space is heating up, and investors will be closely watching to see how Moderna fares in this battle for market share.

Stock Price

On Monday, news coverage of Moderna‘s stock was mostly negative as shares dropped 7% after Pfizer announced its projection of a $10B-$15B mRNA vaccine market by 2030. At the time of writing, Moderna’s stock opened at $175.5 and closed at $165.1, a 6.9% drop from the last closing price of 177.4. As the market matures, investors are expecting that competition will increase. This could mean lower prices for the vaccine and less profits for Moderna in the long run.

However, investors are concerned about how much of this supply will be able to be delivered on time. There have also been reports that Moderna is having difficulty scaling up production and meeting demand. Overall, the news of Pfizer’s projection has caused many investors to become bearish on Moderna’s stock and has caused shares to fall. Despite this, analysts remain optimistic about Moderna’s long-term prospects as the mRNA vaccine market continues to grow. Live Quote…

About the Company

VI Analysis

Moderna is a high risk investment according to the VI Risk Rating, based on the company’s fundamentals. The company’s financial and business aspects have been assessed, and the results indicate that there are risk warnings present in the balance sheet, cash flow statement, non-financial and financial journal. These risk warnings need to be taken into consideration when assessing the company’s long term potential. Investors should carefully consider their own financial situation before investing in Moderna. If they decide to invest, they should be aware of the risks associated with such an investment. Investors should also be aware that any investment carries with it the potential for gain or loss. While Moderna may have a strong long term potential, there is no guarantee that it will perform as expected. Investors should be aware of the risks involved and the potential rewards. Investors should research the company and its financials before making any decisions. They should also monitor the performance of the company over time to ensure that their investment is performing as expected. The VI App can provide investors with detailed insights into the company’s fundamentals and risks associated with investing in Moderna. It can help investors make informed decisions about investing in the company. By registering on VI App, investors can gain access to more detailed information about the company and its risks. More…

VI Peers

Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.

– BioNTech SE ($NASDAQ:BNTX)

BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.

– Novavax Inc ($NASDAQ:NVAX)

Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.

Summary

Investing in Moderna can be a great way to capitalize on the emerging mRNA vaccine market. The company is at the forefront of the industry, having secured contracts for multiple mRNA vaccines, with the most well-known being the COVID-19 vaccine. Moderna has also made significant investments in its research and development, which has enabled it to remain competitive in this rapidly developing sector. Moderna’s stock price has been volatile in recent months due to the uncertainty surrounding the mRNA vaccine market.

However, the company has been working to mitigate this risk by securing partnerships and contracts with governments, pharmaceutical companies, and healthcare organizations. This diversification of revenue sources should reduce Moderna’s risk profile and make it a more attractive investment. Moreover, Moderna is well-placed to benefit from Pfizer’s projection that the mRNA vaccine market size will reach between $10B-$15B by 2030. With its innovative technology and partnerships, Moderna is well-positioned to capitalize on this emerging market. Furthermore, as mRNA vaccines become more widely available, Moderna could benefit from increased demand for its products, which would likely lead to increased profits and a higher stock price. Overall, Moderna is well-positioned to capitalize on the growth of the mRNA vaccine market. While the stock price has been volatile in recent months, the company is taking steps to mitigate its risk profile and increase its revenue sources. Furthermore, with Pfizer’s projection that the mRNA vaccine market could reach between $10B-$15B by 2030, Moderna could be an attractive investment opportunity for investors looking to capitalize on this emerging sector.